NCT03315780View on ClinicalTrials.gov

A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 28, 2017

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
Type 2 Diabetes
Interventions
DRUG

Dulaglutide

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (1)

812-0025

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03315780 - A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes | Biotech Hunter | Biotech Hunter